Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Cytomegalovirus Infection After Transplantation: a Study of New Markers to Optimize the Selection of Antiviral Therapies and Reduce the Risk of Developing Direct and Indirect Infection-related Complications (CMV-TX-2025)

Background and Rationale Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in recipients of solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). Current management relies on antiviral prophylaxis or pre-emptive therapy guided primarily by CMV-DNAemia monitoring. However, recently introduced antivirals such as letermovir and maribavir have changed the virological profile of CMV infection, highlighting limitations of DNAemia as a marker of active viral replication and increasing the need for improved resistance monitoring.

Preliminary studies suggest that CMV-RNAemia (UL21.5 mRNA) may be a more accurate marker of active viral replication and may detect viral clearance approximately 7-14 days earlier than CMV-DNAemia. In parallel, Next Generation Sequencing (NGS) may provide superior detection of antiviral resistance mutations, including low-frequency variants that cannot be identified by conventional Sanger sequencing.

Primary Objective To determine whether using CMV-RNAemia to guide discontinuation of antiviral therapy in transplant recipients can reduce treatment duration and drug-related toxicity without increasing the risk of CMV relapse, compared with the current standard based on CMV-DNAemia.

Secondary Objectives

Compare the diagnostic performance of NGS and Sanger sequencing in detecting CMV antiviral resistance mutations.

Estimate the incidence of resistant or refractory CMV infection (R/R-CMV) in transplant recipients.

Identify risk factors associated with the development of R/R-CMV according to transplant type.

Study Design This is a single-center, pragmatic, randomized controlled interventional study conducted at the IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Adult transplant recipients (≥18 years) with CMV infection requiring antiviral therapy will be randomized (1:1) into two groups:

Experimental arm: antiviral therapy discontinued after two consecutive negative CMV-RNAemia results.

Control arm: antiviral therapy discontinued after two consecutive negative CMV-DNAemia results.

Patients will be followed from treatment initiation, with virological monitoring continuing during therapy and follow-up.

Population and Sample Size The study plans to enroll approximately 330 CMV infection episodes, including an estimated 10% drop-out rate, with 150 participants per study arm plus additional cases to compensate for losses.

Endpoints Primary endpoints include:

Time to treatment discontinuation. Time to viral clearance. Incidence and timing of clinically significant CMV relapse. Antiviral drug toxicity.

Secondary endpoints include:

Sensitivity, specificity, and predictive value of NGS versus Sanger sequencing. Incidence of resistant/refractory CMV infection. Identification of clinical and virological risk factors for resistance.

Resistance Analysis In suspected resistant or refractory CMV infections, residual biological samples will undergo NGS analysis targeting CMV genes involved in antiviral resistance (UL97, UL54, UL56, UL89, UL27, UL51). Results will be compared with standard Sanger sequencing to assess earlier detection of resistance mutations and minor viral variants.

Expected Impact The study aims to establish CMV-RNAemia as a clinically useful marker for earlier identification of viral clearance, enabling shorter antiviral treatment and reduced toxicity. It also seeks to validate NGS-based resistance testing as a more sensitive tool for detecting emerging CMV drug resistance, ultimately supporting a more personalized approach to CMV management in transplant recipients and potentially other immunocompromised populations.

Study Duration and Funding The study is expected to last 24 months (18 months recruitment, 4 months follow-up, 2 months analysis) and is funded by the Italian Ministry of Health (Ricerca Corrente 2026, project RC-2026-2802099).

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

330

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Italy
      • Bologna, Italy, Italia, 40138
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • CSE/SOT transplant patient;
  • Currently receiving antiviral medication;
  • Age ≥ 18 years
  • Signed informed consent form for participation and data processing

Exclusion Criteria:

  • Localized CMV infection / organ disease.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Antiviral therapy will be discontinued after two consecutive negative results for CMV-RNAemia

From enrollment (time 0, t0) until viral clearance is achieved (tn), all remaining biological material from blood samples analyzed for the monitoring/diagnosis of CMV infection will be collected and stored. Plasma samples will be analyzed for the presence of UL21.5 mRNA (CMV-RNAemia UL21.5) using the automated CMV-RNA ELITe MGB kit on an InGenius instrument (ELITech Group).

During the treatment period and the follow-up period, patients will be monitored in accordance with current clinical practice through serial virologic assessments (CMV-DNAemia) and the collection of relevant clinical data. Assessments will be conducted weekly during the first three months after transplantation, every 15 days from the fourth to the sixth month, and then monthly from the seventh to the twelfth month. For the purposes of evaluating the primary endpoint, the first four months of follow-up will be taken into account.

Comparatore attivo: Antiviral therapy will be discontinued after two consecutive negative results for CMV-DNAemia

During the treatment period and the follow-up period, patients will be monitored in accordance with current clinical practice through serial virologic assessments (CMV-DNAemia) and the collection of relevant clinical data. Assessments will be conducted weekly during the first three months after transplantation, every 15 days from the fourth to the sixth month, and then monthly from the seventh to the twelfth month. For the purposes of evaluating the primary endpoint, the first four months of follow-up will be taken into account.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
CMV-DNAemia VS CMV-DNAemia 1
Lasso di tempo: Periprocedural

To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection.

Measure: Time to discontinuation of therapy

Periprocedural
CMV-DNAemia VS CMV-DNAemia 2
Lasso di tempo: Periprocedural

To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection.

Measure: Time to viral clearance

Periprocedural
CMV-DNAemia VS CMV-DNAemia 3
Lasso di tempo: Follow-up analysis (up to 4 months)

To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection.

Measure: Incidence and time to recurrence of clinically significant CMV infection

Follow-up analysis (up to 4 months)
CMV-DNAemia VS CMV-DNAemia 4
Lasso di tempo: Periprocedural

To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection.

Measure: Toxicity associated with anti-CMV drugs

Periprocedural

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Sanger sequencing VS NGS sequencing 1
Lasso di tempo: Follow up analysis (up to 1 year)

Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants.

Measure: Sensitivity and specificity of NGS compared to Sanger

Follow up analysis (up to 1 year)
Incidence of refractory CMV infection
Lasso di tempo: Follow up analysis (up to 1 year)

To estimate the incidence of resistant or refractory CMV infection (R/R CMV) in transplant recipients (SOT and CSE).

Measure: Incidence of resistant or refractory CMV infection

Follow up analysis (up to 1 year)
Risk factors for refractory CMV infection
Lasso di tempo: Follow up analysis (up to 1 year)

To compare the risk factors associated with the development of resistant or refractory CMV infection (R/R CMV) by type of transplant.

Measure: Risk factors associated with resistant or refractory CMV infection

Follow up analysis (up to 1 year)
Sanger sequencing VS NGS sequencing 2
Lasso di tempo: Follow up analysis (up to 1 year)

Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants.

Measure: Predictive value of NGS compared to Sanger

Follow up analysis (up to 1 year)
Sanger sequencing VS NGS sequencing 3
Lasso di tempo: Follow up analysis (up to 1 year)

Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants.

Measure: Time required to identify mutations using NGS compared to Sanger

Follow up analysis (up to 1 year)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 giugno 2028

Completamento dello studio (Stimato)

1 giugno 2028

Date di iscrizione allo studio

Primo inviato

5 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • CMV-TX-2025
  • WFR 2802099 (Altro numero di sovvenzione/finanziamento: Italian Ministry of Health)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .